Novo Nordisk Loses Another Executive as 28-Year Veteran Departs
Novo Nordisk A/S executive Camilla Sylvest is leaving the Danish drugmaker after almost three decades, the company's second high-profile departure in a month as it battles to maintain its share of the booming market for weight-loss treatments.
Sylvest, part of the leadership team, spent the last seven years as executive vice president for commercial strategy and corporate affairs at Novo Nordisk, and was close to Chief Executive Officer Lars Fruergaard.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
IQVIA Holdings (NYSE:IQV) Sees 11% Share Price Rise Over Last Week
IQVIA Holdings experienced a 10% rise in share price over the last week, correlating with its recent developments, notably the dosing of the first patient in the RENEW Phase 2 trial and its strategic alliance with Sarah Cannon Research Institute to optimize oncology trials. These initiatives likely provided a positive sentiment boost, aligning well with the broader market momentum, as indices such as the S&P 500 also reached new highs. The market's anticipation over US-China trade talks and overall strong corporate earnings have supported the upward trend, further enhancing IQV's market performance. We've identified 1 warning sign for IQVIA Holdings that you should be aware of. Uncover 18 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent 10% rise in IQVIA Holdings' share price has been influenced by important developments like the dosing in the RENEW Phase 2 trial and a key alliance with Sarah Cannon Research Institute. These initiatives are expected to potentially drive revenue growth, particularly as the strategic alliance optimizes oncology trials. The company's past performance, with total returns of 10.45% over five years, suggests modest growth in investor value. However, compared to the US Life Sciences industry's one-year return of 27% decline, IQVIA's recent rise highlights positive market sentiment. These initiatives, combined with FDA reforms and NVIDIA collaboration, may lower operational costs and have a favorable impact on earnings forecasts. Analysts predict revenue to grow by 5.2% annually over the next three years, which is somewhat cautious compared to the general expectations for the life sciences sector. The recent share price movement to US$146.2 remains below the consensus price target of US$216.31, indicating potential for future appreciation if the projected growth in revenue and earnings materializes. Click here to discover the nuances of IQVIA Holdings with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
'So bad, it's good': History shows the market's smallest stocks may be poised for a rebound after record underperformance
Small-cap stocks look poised for a rebound this month after tariff-related losses. Historically, June sees strong small-cap performance due to FTSE Russell index rebalancing. Cheap valuations, potential rate cuts, and AI adoption could drive a small-cap resurgence. Small-cap stocks were hammered in the aftermath of President Donald Trump's tariffs, but the stage looks set for a rebound this June. The small-cap track record has been grim recently: the Russell 2000 has seen its worst streak of underperformance relative to the S&P 500 since the dot-com era, and this past May marked the sixth-worst year-to-date performance since 1990. Small caps, initially perceived as a clear winner of the Trump trade following the election, have emerged as the biggest losers of the trade war. With tariff concerns top-of-mind, investors are viewing small caps as "price takers, not price makers," extra vulnerable to inflation and supply chain disruptions, a note by Evercore ISI senior managing direction, Julian Emanuel, said. But for the optimists, once you hit rock bottom, the only direction to go is up. In the eyes of Evercore, small caps have become "so bad, they're good." June has historically been a strong month for small caps, as the FTSE Russell rebalances its indexes and adds or removes stocks based on market cap criteria. This leads to a surge of trading activity that can boost stock prices. This effect is particularly prominent in the wake of outsized underperformance. In the five other instances of disappointing January to May performance, small caps exhibited strong seasonal reversion during the month of June, outperforming large caps by an average of 4.1%, Evercore said. The firm believes the market has moved past the point of peak tariff uncertainty, which could further boost the sector's performance in June. There are other catalysts for a small-cap resurgence as well. Amy Zhang, a portfolio manager at investment management firm Alger, pointed to cheap valuations and the potential for rate cuts. Small caps have historically traded at a 27% premium relative to large caps due to their higher growth expectations, but on a forward-looking basis, the Russell 2000 is currently only trading at a 11% premium to the S&P 500. This allows investors to get exposure to small caps at a steep discount relative to history, especially as fundamentals and the overall economic environment improve. Cheap valuations make small caps appealing takeover targets, and a pickup in M&A activity could help lift the group, Zhang told Business Insider. As large companies look to boost growth through acquisitions, smaller firms become prime candidates. The healthcare sector, the largest component of the Russell 2000, tends to benefit the most from increased dealmaking, according to Bank of America. Both Emanuel and Zhang believe lower rates, which help smaller companies with higher levels of debt on their balance sheets, could be coming later this year. "Because it's data dependent, they run the risk of being too late again," Zhang said of the Fed cutting rates. "I think it could be the case, like last year Q4, where the Fed may be in a position again to pivot to 50 basis points of cuts." Additionally, Zhang sees AI as a long-term tailwind for small caps. "AI is very deflationary, especially for labor costs," Zhang said. That means companies that adopt AI effectively can expand margins and boost productivity — advantages that could be especially powerful for smaller firms with with smaller budgets. Read the original article on Business Insider
CNBC
34 minutes ago
- CNBC
Uncertainty looms as 2025 nears the halfway mark. How to make sure your portfolio is prepared
Stocks have made a recovered from this year's lows, but uncertainty remains a key theme as the second half of the year approaches – and investors can prepare for it. President Donald Trump's rollout of sharply higher tariffs in April sent stocks on a wild ride, with the S & P 500 at one point dipping more than 20% from its all-time high. Traders' hopes for progress in trade negotiations, along with solid first-quarter earnings, helped the market recover since then, however. The S & P 500 is now less than 2% below its its all-time high. Don't just kick back and wait for a continued recovery, though. "Our little tagline here is 'diversifying for resilience,'" said Michael Arone, SPDR chief investment strategist at State Street Global Advisors. "The thought behind the theme for the second half, is that markets are in suspense," he said. Some of the issues for investors to cinsider now include trade policy, soft economic data and the chance that the Federal Reserve holds off on rate cuts for too long, Arone added. Here's how to get your portfolio ready for the remainder of the year Review and rebalance Ignoring your portfolio's asset allocation, particularly at a time when markets are strong, can result in lopsided positions. For starters, think about how large-cap tech stocks in the U.S. were responsible for the market's surge last year. Failure to prune some of those big positions now, and add to underweight sectors, could result in a portfolio that doesn't reflect your goals and risk appetite. This year, investors who shied away from international markets may have found themselves missing out on sizable appreciation. Consider that the Vanguard FTSE All-World ex-US ETF (VEU) has returned 16% in 2025, while the S & P 500's return over the same period is a little more than 2%. VEU .SPX YTD mountain The Vanguard FTSE All-World ex-US ETF (VEU) versus the S & P 500 in 2025 "If we look through a stock lens, U.S. allocation peaked at 67%, and today it's at 64%," said Arone. "I can tell you there are very few investors I meet with who have 36% of their portfolio invested outside of the U.S. from a stock standpoint." Diversifying into international funds also helps investors gain exposure to sectors outside of Big Tech, said Christine Benz, director of personal finance and retirement planning for Morningstar. "The U.S. is still very tech dominated and growth leaning, but broad non-U.S. indexes are dominated by financials and health care. It's a different set of market components relative to the U.S." Benz likes the idea of investors using a broad global stock benchmark as a guide to determine how much to invest overseas, noting that the split is generally about 60% toward the U.S. and 40% non-U.S. Reassess your goals and risk appetite The market's slide in April might have been a good chance for investors to do a gut check of whether their asset allocation reflects the risk they are willing to take. "My big [issue] is the value of derisking for people who are getting close to retirement," said Benz. "It might not have felt like a great idea to derisk in the throes of tariff-related market losses, but now stocks have clawed their way back into positive territory." Investors who are nearing retirement might want to consider adding safer assets to their portfolios to take advantage of today's higher yields, she added. "Consider taking advantage of the fact that yields are decent today and it will translate to better returns for fixed income versus when yields were very low," said Benz. For savers in retirement plans, this can also mean reviewing where you're directing your contributions. "Let's say you're not ready to retire, but retirement is in the next five to 10 years," said Marguerita Cheng, CFP and chief executive officer of Blue Ocean Global Wealth in Gaithersburg, Md. "You can have some of your existing dollars in something a little more conservative, and when you dollar-cost average you can be a little more growth oriented," she said. Dollar-cost averaging refers to making incremental investments into a certain asset at fixed intervals, say every two weeks, every month or every quarter. By spreading out these investments, you're buying into stocks at different prices over time, instead of trying to wait for the "right" time. Tax-loss harvesting Tax-loss harvesting opportunities may await investors who have taxable brokerage accounts. This involves selling losing positions and using the realized losses to offset gains elsewhere in the portfolio. Be sure to avoid violating the wash-sale rule, which involves selling an asset at a loss and then buying a "substantially identical" security within 30 days before or after the transaction. In such cases, the IRS can block you from taking the loss. Lagging stock sectors this year include energy, health care and consumer discretionary, which might all be solid contenders for tax-loss sales. "Investors with individual stocks, sector funds or ETFs might have an opportunity to take a tax loss in those areas," said Benz.
